Comparative Pharmacology
Head-to-head clinical analysis: CARISOPRODOL COMPOUND versus PARSIDOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARISOPRODOL COMPOUND versus PARSIDOL.
CARISOPRODOL COMPOUND vs PARSIDOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carisoprodol is a centrally acting muscle relaxant that acts as a prodrug for meprobamate, a barbiturate-like compound with sedative and anxiolytic properties. Its mechanism is thought to involve GABA-A receptor modulation and depression of polysynaptic reflexes in the spinal cord and reticular formation. Aspirin provides analgesic and anti-inflammatory effects via irreversible inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Codeine is an opioid agonist at mu-opioid receptors, producing analgesia by mimicking endogenous endorphins.
Parsidol (ethopropazine) is a phenothiazine derivative that acts as an anticholinergic agent. It inhibits the action of acetylcholine at muscarinic receptors, thereby reducing cholinergic activity in the basal ganglia and restoring the balance between dopaminergic and cholinergic neurotransmission. It also has some dopamine reuptake inhibition and antihistaminic properties.
1-2 tablets (carisoprodol 200 mg/aspirin 325 mg) orally 4 times daily.
Oral: 2.5-5 mg twice daily, gradually increased to 5-10 mg three times daily; maximum 60 mg/day.
None Documented
None Documented
Carisoprodol has a terminal elimination half-life of approximately 1.5–2 hours; its active metabolite meprobamate has a half-life of 9–12 hours, which may lead to prolonged effects with chronic use.
Terminal elimination half-life: 12-24 hours (prolonged in elderly and renal impairment, requiring dose adjustment).
Carisoprodol is primarily metabolized in the liver, with about 50% excreted renally as unchanged drug and metabolites; the major metabolite meprobamate is also renally excreted. Fecal excretion is negligible (<2%).
Renal: 60-70% as unchanged drug; biliary/fecal: 15-20% as metabolites; minor respiratory elimination.
Category A/B
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant